PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.68%
Revenue growth near Medical - Pharmaceuticals median of 4.67%. Charlie Munger would verify if industry-standard growth is attractive.
4.02%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 2.50%. Jim Chanos would check for structural cost disadvantages.
7.34%
Gross profit growth 1.25-1.5x Medical - Pharmaceuticals median of 5.97%. Mohnish Pabrai would examine sustainability.
2.55%
Margin change of 2.55% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.62%
Other expenses change of 25.62% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
5.78%
Operating expenses growth 50-90% of Medical - Pharmaceuticals median of 7.60%. Mohnish Pabrai would examine discipline.
4.31%
Total costs growth 50-90% of Medical - Pharmaceuticals median of 6.90%. Mohnish Pabrai would examine discipline.
-7.69%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
7.42%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.63%. Jim Chanos would check for overinvestment.
10.15%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
5.23%
Margin change of 5.23% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
14.18%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
9.08%
Margin change of 9.08% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-10.79%
Other expenses reduction while Medical - Pharmaceuticals median is -8.76%. Seth Klarman would investigate advantages.
11.47%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
6.49%
Margin change of 6.49% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-23.59%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
28.60%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
22.85%
Margin change of 22.85% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
28.61%
EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
28.61%
Diluted EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.